The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome
Open accessAbstract
BACKGROUND. Hepatitis C virus (HCV) infects approximately 170 million people worldwide and may lead to cirrhosis and hepatocellular carcinoma in chronically infected individuals. Treatment is rapidly evolving from IFN-α-based therapies to IFN-α-free regimens that consist of directly acting antiviral agents (DAAs), which demonstrate improved efficacy and tolerability in clinical trials. Virologic relapse after DAA therapy is a common cause of treatment failure; however, it is not clear why relapse occurs or whether certain individuals are more prone to recurrent viremia. METHODS. We conducted a clinical trial using the DAA sofosbuvir plus ribavirin (SOF/RBV) and performed detailed mRNA expression analysis in liver and peripheral blood from patients who achieved either a sustained virologic response (SVR) or relapsed. RESULTS. On-treatment viral clearance was accompanied by rapid downregulation of IFN-stimulated genes (ISGs) in liver and blood, regardless of treatment outcome. Analysis of paired pretreatment and end of treatment (EOT) liver biopsies from SVR patients showed that viral clearance was accompanied by decreased expression of type II and III IFNs, but unexpectedly increased expression of the type I IFN IFNA2. mRNA expression of ISGs was higher in EOT liver biopsies of patients who achieved SVR than in patients who later relapsed. CONCLUSION. These results suggest that restoration of type I intrahepatic IFN signaling by EOT may facilitate HCV eradication and prevention of relapse upon withdrawal of SOF/RBV. TRIAL REGISTRATION. ClinicalTrials.gov NCT01441180.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Immune surveillance by the liver
Jenne, C. N., & Kubes, P. (2013) · Nature Immunology · doi:10.1038/ni.2691 · Cited by 1,047
Cited by
Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., Díaz, A., Vilana, R., Darnell, A., Varela, M., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.008 · Cited by 1,018
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.045 · Cited by 419
Goldstein, I., Paakinaho, V., Baek, S., Sung, M.-H., & Hager, G. L. (2017) · Nature Communications · doi:10.1038/s41467-017-02055-5 · Cited by 97
Chronic hepatitis C infection–induced liver fibrogenesis is associated with M2 macrophage activation
Bility, M. T., Nio, K., Li, F., McGivern, D. R., Lemon, S. M., Feeney, E. R., Chung, R. T., & Su, L. (2016) · Scientific Reports · doi:10.1038/srep39520 · Cited by 71
Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis
Cui, A., Li, B., Wallace, M. S., Gonye, A. L. K., Oetheimer, C., Patel, H., Tonnerre, P., Holmes, J. A., Lieb, D., Yao, B. S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.040 · Cited by 46
Metadata
- Authors
- Meissner, E. G., Wu, D., Osinusi, A., Bon, D., Virtaneva, K., Sturdevant, D., Porcella, S., Wang, H., Herrmann, E., McHutchison, J., Suffredini, A. F., Polis, M., Hewitt, S., Prokunina-Olsson, L., Masur, H., Fauci, A. S., & Kottilil, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-07-01
- Volume
- 124
- Issue
- 8
- Pages
- 3352-3363
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2059311032
- Cited by
- 201
- References
- 2
- FWCI
- 13.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. https://app.cochat.ai/papers/10.1172/jci75938
- The paper
- Meissner, E. G., Wu, D., Osinusi, A., Bon, D., Virtaneva, K., Sturdevant, D., Porcella, S., Wang, H., Herrmann, E., McHutchison, J., Suffredini, A. F., Polis, M., Hewitt, S., Prokunina-Olsson, L., Masur, H., Fauci, A. S., & Kottilil, S. (2014). Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. Journal of Clinical Investigation. https://doi.org/10.1172/jci75938
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.